Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (191-200 of 910) with videos related to

Pageof 91
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 10, 2006
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS dataPaul W Armstrong, Wei-Ching Chang, Lars Wallentin, et al.
Circulation. Cardiovascular Interventions|April 4, 2013
Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomesJeffrey T Guptill, Rajendra H Mehta, Paul W Armstrong, et al.
Journal of the American College of Cardiology|October 2, 2002
Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capabilityRajendra H Mehta, Douglas A Criger, Christopher B Granger, et al.
Journal of Electrocardiology|May 24, 2014
Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarctionMike H Bao, Yinggan Zheng, Cynthia M Westerhout, et al.
Journal of Thrombosis and Thrombolysis|October 28, 2021
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomesJay S Shavadia, Wendimagegn Alemayehu, Christopher deFilippi, et al.
JACC. Cardiovascular Interventions|October 24, 2009
The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary interventionAllan M Ross, Kurt Huber, Uwe Zeymer, et al.
American Heart Journal|February 22, 2003
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and CanadaWayne B Batchelor, Daniel B Mark, J David Knight, et al.
American Heart Journal|July 2, 2005
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarctionPadma Kaul, Paul W Armstrong, Patricia A Cowper, et al.
The New England Journal of Medicine|September 13, 2013
Randomized clinical trials--removing unnecessary obstaclesChristina Reith, Martin Landray, P J Devereaux, et al.
Nature Cardiovascular Research|March 18, 2026
Decentralized clinical trials in cardiovascular disease : A primer for clinical trialistsGuillaume Baudry, Prashanth Kulkarni, Tor Biering-Sørensen, et al.
Pageof 91

Showing results (191-200 of 910) with videos related to

Sort By:
Pageof 91
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 10, 2006
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS dataPaul W Armstrong, Wei-Ching Chang, Lars Wallentin, et al.
Circulation. Cardiovascular Interventions|April 4, 2013
Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomesJeffrey T Guptill, Rajendra H Mehta, Paul W Armstrong, et al.
Journal of the American College of Cardiology|October 2, 2002
Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capabilityRajendra H Mehta, Douglas A Criger, Christopher B Granger, et al.
Journal of Electrocardiology|May 24, 2014
Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarctionMike H Bao, Yinggan Zheng, Cynthia M Westerhout, et al.
Journal of Thrombosis and Thrombolysis|October 28, 2021
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomesJay S Shavadia, Wendimagegn Alemayehu, Christopher deFilippi, et al.
JACC. Cardiovascular Interventions|October 24, 2009
The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary interventionAllan M Ross, Kurt Huber, Uwe Zeymer, et al.
American Heart Journal|February 22, 2003
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and CanadaWayne B Batchelor, Daniel B Mark, J David Knight, et al.
American Heart Journal|July 2, 2005
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarctionPadma Kaul, Paul W Armstrong, Patricia A Cowper, et al.
The New England Journal of Medicine|September 13, 2013
Randomized clinical trials--removing unnecessary obstaclesChristina Reith, Martin Landray, P J Devereaux, et al.
Nature Cardiovascular Research|March 18, 2026
Decentralized clinical trials in cardiovascular disease : A primer for clinical trialistsGuillaume Baudry, Prashanth Kulkarni, Tor Biering-Sørensen, et al.
Pageof 91